Source: Trial designRetatrutide
Retatrutide 12 mg: how the TRIUMPH trials escalated the dose
TRIUMPH-2/3 started retatrutide at 2 mg weekly and stepped up every 4 weeks (2 → 4 → 6 → 9 → 12 mg). Retatrutide is investigational and not approved. Sources linked.
Quickstart highlights
- Investigational — not FDA-approved; Lilly plans to file in Q1 2027.
- Trial start dose 2 mg weekly; steps every 4 weeks.
- Target arms: 4, 9 and 12 mg (TRIUMPH-2); 9 and 12 mg (TRIUMPH-3).
Dosing table
| Step | Dose | Duration |
|---|---|---|
| Weeks 1–4 | 2 mg | 4 weeks |
| Weeks 5–8 | 4 mg | 4 weeks (target for 4 mg arm) |
| Weeks 9–12 | 6 mg | 4 weeks |
| Weeks 13–16 | 9 mg | 4 weeks (target for 9 mg arm) |
| Week 17 onward | 12 mg | Target for 12 mg arm |
Protocol overview & notes
This is how a pharmaceutical sponsor escalated an unapproved drug under medical supervision in a controlled trial. It is reported here because people search for it; it is not a recommendation, and products sold online as "retatrutide" are not the trial drug.
Storage & handling
Not applicable — there is no approved product.
How this works & references
Every row of the table above is copied from the source listed below; we change nothing except layout. If the source is revised, we update this page and its date.
Sources
Frequently asked questions
What doses of retatrutide were tested in Phase 3?
4, 9 and 12 mg once weekly in TRIUMPH-2, and 9 and 12 mg in TRIUMPH-3, reached by 4-week steps from 2 mg.
Is retatrutide approved?
No. It is investigational; Lilly plans to submit a BLA in Q1 2027.
Is this a dosing guide?
No. It reports a published trial design for reference.